company background image
ORTX

Orchard Therapeutics NasdaqCM:ORTX Stock Report

Last Price

US$7.36

Market Cap

US$170.2m

7D

22.7%

1Y

49.0%

Updated

25 Sep, 2023

Data

Company Financials +

Orchard Therapeutics plc

NasdaqCM:ORTX Stock Report

Mkt Cap: US$170.2m

ORTX Stock Overview

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.

ORTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Orchard Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orchard Therapeutics
Historical stock prices
Current Share PriceUS$7.36
52 Week HighUS$7.39
52 Week LowUS$3.60
Beta0.92
1 Month Change48.24%
3 Month Change40.73%
1 Year Change48.96%
3 Year Change-82.52%
5 Year Changen/a
Change since IPO-94.74%

Recent News & Updates

Recent updates

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

May 09
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Mar 10
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Aug 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

FDA signs-off Orchard Therapeutics' gene therapy for rare nerve cell disorder

Nov 19

Orchard Therapeutics EPS beats by $0.26, beats on revenue

Nov 03

Shareholder Returns

ORTXUS BiotechsUS Market
7D22.7%-1.8%-3.1%
1Y49.0%10.3%15.1%

Return vs Industry: ORTX exceeded the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: ORTX exceeded the US Market which returned 15.1% over the past year.

Price Volatility

Is ORTX's price volatile compared to industry and market?
ORTX volatility
ORTX Average Weekly Movement7.4%
Biotechs Industry Average Movement9.0%
Market Average Movement5.5%
10% most volatile stocks in US Market14.2%
10% least volatile stocks in US Market2.5%

Stable Share Price: ORTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ORTX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015166Bobby Gasparhttps://www.orchard-tx.com

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.

Orchard Therapeutics plc Fundamentals Summary

How do Orchard Therapeutics's earnings and revenue compare to its market cap?
ORTX fundamental statistics
Market CapUS$170.24m
Earnings (TTM)-US$85.17m
Revenue (TTM)US$21.31m

8.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORTX income statement (TTM)
RevenueUS$21.31m
Cost of RevenueUS$83.09m
Gross Profit-US$61.78m
Other ExpensesUS$23.39m
Earnings-US$85.17m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.68
Gross Margin-289.85%
Net Profit Margin-399.58%
Debt/Equity Ratio25.6%

How did ORTX perform over the long term?

See historical performance and comparison